Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 1688 results for carers

  1. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910

    Awaiting development [GID-TA11403] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis TS ID 11905

    Awaiting development [GID-TA11414] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642

    Awaiting development [GID-TA11308] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147

    Awaiting development [GID-TA11327] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550

    Awaiting development [GID-TA11354] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865

    Awaiting development [GID-TA11358] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

    Awaiting development [GID-TA11254] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older TSID 11995

    Awaiting development [GID-TA11525] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996

    Awaiting development [GID-TA11526] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zavegepant for treating acute migraine TSID 11998

    Awaiting development [GID-TA11527] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991

    Awaiting development [GID-TA11518] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development